Search results for "tumor vaccination"

showing 6 items of 6 documents

CIMT 2019: report on the 17th Annual Meeting of the Association for Cancer Immunotherapy

2019

The 17th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe`s cancer immunotherapy meeting, took place in Mainz, Germany from 21 to 23 May, 2019. Recent advancements in cance...

Oncologymedicine.medical_specialtyCombination therapymedicine.medical_treatment030231 tropical medicineImmunologyMeeting ReportCancer Vaccinescombination therapyCell therapy03 medical and health sciences0302 clinical medicineCancer immunotherapyNeoplasmsInternal medicineTumor MicroenvironmentHumansImmunology and AllergyMedicine030212 general & internal medicinetumor vaccinationPersonalized therapypersonalized therapyPharmacologyTumor microenvironmentcancer immunotherapybusiness.industryCIMTcellular therapyCongresses as Topiccheckpoint blockadeImmunotherapybusinessHuman Vaccines & Immunotherapeutics
researchProduct

CIMT 2016: Mechanisms of efficacy in cancer immunotherapy — Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10–12 2…

2016

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyMeeting Reportcombination therapyCell therapy03 medical and health sciencesCancer immunotherapyInternal medicineantibodiestumor microenvironmentImmunology and AllergyMedicinetumor vaccinationPersonalized therapypersonalized therapyPharmacologyTumor microenvironmentcancer immunotherapybusiness.industryCIMTcellular therapy030104 developmental biologyImmunologycheckpoint blockadebusinessHuman Vaccines & Immunotherapeutics
researchProduct

CIMT 2018: Pushing frontiers in cancer immunotherapy — Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy

2018

ABSTRACT The 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe’s largest meeting series of its kind, took place in Mainz, Germany from 15–17 May, 2018. Cutting-edge advancements in cancer immunotherapy were discussed among more than 700 scientists under the motto “Pushing Frontiers in Cancer Immunotherapy”. This meeting report is a summary of some of the CIMT 2018 highlights.

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyMeeting Reportcombination therapyCell therapy03 medical and health sciencesCancer immunotherapyInternal medicineNeoplasmsmedicineTumor MicroenvironmentImmunology and AllergyAnimalsHumansPersonalized therapytumor vaccinationPharmacologypersonalized therapyTumor microenvironmentcancer immunotherapybusiness.industryVaccinationCIMTcellular therapyCongresses as TopicXenograft Model Antitumor AssaysDisease Models Animal030104 developmental biologycheckpoint blockadeDrug Therapy CombinationImmunotherapybusinessHuman Vaccines & Immunotherapeutics
researchProduct

CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy

2017

The 15th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) took place May 10–11, 2017, Mainz, Germany during which scientists and CIMT members from all over the world not only celeb...

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyPhysiologyMeeting Reportcombination therapyCell therapy03 medical and health sciences0302 clinical medicineCancer immunotherapyInternal medicinemedicineImmunology and Allergyantibodiestumor microenvironmentPersonalized therapytumor vaccinationPharmacologypersonalized therapycancer immunotherapybusiness.industryCIMTcellular therapy030104 developmental biology030220 oncology & carcinogenesischeckpoint blockadebusinessHuman Vaccines & Immunotherapeutics
researchProduct

Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma

2018

The advent of immune checkpoint (ICP) blockade has introduced an unprecedented paradigm shift in the treatment of cancer. Though very promising, there is still a substantial proportion of patients who do not respond or develop resistance to ICP blockade. In vitro and in vivo models are eagerly needed to identify mechanisms to maximize the immune potency of ICP blockade and overcome primary and acquired resistance to ICP blockade. Vγ9Vδ2 T cells isolated from the bone marrow (BM) from multiple myeloma (MM) are excellent tools to investigate the mechanisms of resistance to PD-1 blockade and to decipher the network of mutual interactions between PD-1 and the immune suppressive tumor microenvir…

0301 basic medicineCancer Researchmedicine.medical_treatmentMini Reviewlcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemIn vivoMedicinetumor vaccinationVg9Vd2 T cells immune checkpoint blockade immunotherapy tumor vaccination multiple myelomaMultiple myelomaTumor microenvironmentVg9Vd2 T cellsbusiness.industryImmunotherapyimmune checkpoint blockadelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseVγ9Vδ2 T cellsImmune checkpointBlockademultiple myeloma030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchBone marrowimmunotherapybusinessFrontiers in Oncology
researchProduct

CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy

2015

The 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) brought together more than 800 scientists in Mainz, Germany, from May 11–13, 2015, to present and discuss current research...

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyMeeting Reportcombination therapyCell therapy03 medical and health sciencesCancer immunotherapyInternal medicinemedicineImmunology and Allergytumor microenvironmentPersonalized therapytumor vaccinationPharmacologypersonalized therapyTumor microenvironmentcancer immunotherapybusiness.industryCIMTcellular therapy030104 developmental biologyImmunologybusinessHuman Vaccines & Immunotherapeutics
researchProduct